MedTrace Logo

Echoplanar Imaging Thrombolysis Evaluation Trial (EPITHET)

NCT00238537 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-05-30

No results posted yet for this study

Summary

To determine whether the extent of the ischemic penumbra apparent on perfusion-diffusion MRI can be used to identify patients who would respond positively and safely to tissue plasminogen activator (tPA) beyond 3 hours post-stroke.

Conditions

Interventions

DRUG

Alteplase t-PA

Sponsors & Collaborators

Principal Investigators

  • Stephen M Davis, MD FRCP FRACP · Melbourne Health

  • Geoffrey Donnan, MD FRACP · National Stroke Research Institute, Australia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-08-31
Completion
2007-04-30

Countries

  • Australia
  • Belgium
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00238537 on ClinicalTrials.gov